Loading
A phase 2 trial of Intismeran autogene in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) is a phase 2 interventional study registered as NCT06833073 by Merck Sharp & Dohme LLC, with 308 participants planned, started 2025-03-11 and due to reach its primary completion in 2031-09-03. Interventions recorded: Intismeran autogene and BCG.
Shares Non-muscle-invasive bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.